Skip to content

Research at St Andrews

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Research output: Contribution to journalArticle

Author(s)

Conor D. Tweed, Angela M. Crook, Evans I. Amukoye, Rodney Dawson, Andreas H. Diacon, Madeline Hanekom, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Michael E. Murphy, Saraswathi E. Murthy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Genevieve H. Wills, Stephen H. Gillespie

School/Research organisations

Abstract

Background:  The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard regimen and two experimental regimens containing moxifloxacin.
Methods:  All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded. Univariable logistic regression was used to test the relationship of baseline characteristics to the incidence of grade 3 & 4 AEs and significant characteristics (p < 0.10) were incorporated into a multivariable model. The timing of AEs during therapy was analysed in standard therapy and the experimental arms. Logistic regression was used to investigate the relationship between AEs (total and related-only) and microbiological cure on treatment.
Results:  In the standard therapy arm 57 (8.9%) of 639 patients experienced ≥1 related AEs with 80 of the total 113 related events (70.8%) occurring in the intensive phase of treatment. Both four-month experimental arms (“isoniazid arm” with moxifloxacin substituted for ethambutol & “ethambutol arm” with moxifloxacin substituted for isoniazid) had a lower total of related grade 3 & 4 AEs than standard therapy (63 & 65 vs 113 AEs). Female gender (adjOR 1.97, 95% CI 0.91–1.83) and HIV-positive status (adjOR 3.33, 95% CI 1.55–7.14) were significantly associated with experiencing ≥1 related AE (p < 0.05) on standard therapy. The most common adverse events on standard therapy related to hepatobiliary, musculoskeletal and metabolic disorders. Patients who experienced ≥1 related AE were more likely to fail treatment or relapse (adjOR 3.11, 95% CI 1.59–6.10, p < 0.001).
Conclusions:  Most AEs considered related to standard therapy occurred in the intensive phase of treatment with female patients and HIV-positive patients demonstrating a significantly higher risk of AEs during treatment. Almost a tenth of standard therapy patients had a significant side effect, whereas both experimental arms recorded a lower incidence of toxicity. That patients with one or more AE are more likely to fail treatment suggests that treatment outcomes could be improved by identifying such patients through targeted monitoring.
Close

Details

Original languageEnglish
Article number317
Number of pages11
JournalBMC Infectious Diseases
Volume18
DOIs
StatePublished - 11 Jul 2018

    Research areas

  • Tuberculosis, Toxicity, Clinical trials, Adverse events

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Wills, G. H., Crook, A. M., Dawson, R., Diacon, A. H., Louw, C. E., McHugh, T. D., Mendel, C., Meredith, S., Mohapi, L., Murphy, M. E., Murray, S., Murthy, S., Nunn, A. J., Phillips, P. P. J., Singh, K., Spigelman, M. & Gillespie, S. H. 28 Mar 2018 In : BMC Medicine. 16, 10 p., 46

    Research output: Contribution to journalArticle

  2. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

    Murphy, M. E., Wills, G. H., Murthy, S., Louw, C., Bateson, A. L. C., Hunt, R. D., McHugh, T. D., Nunn, A. J., Meredith, S. K., Mendel, C. M., Spigelman, M., Crook, A. M., Gillespie, S. H. & REMoxTB Consortium 17 Oct 2018 In : BMC Medicine. 16, 11 p., 189

    Research output: Contribution to journalArticle

  3. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

    Ahmed, M. I. M. , Ntinginya, N. E. , Kibiki, G. , Mtafya, B. A. , Semvua, H. , Mpagama, S. , Mtabho, C. , Saathoff, E. , Held, K. , Loose, R. , Kroidl, I. , Chachage, M. , Both, U. V. , Haule, A. , Mekota, A-M. , Boeree, M. J. , Gillespie, S. H. , Hoelscher, M. , Heinrich, N. , Geldmacher, C. & 1 others Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 28 Sep 2018 In : Frontiers in Immunology. 9, 13 p., 2247

    Research output: Contribution to journalArticle

  4. Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

    Kennedy, J. A., Baron, V. O., Hammond, R. J. H., Sloan, D. J. & Gillespie, S. H. 1 Aug 2018 In : Tuberculosis.

    Research output: Contribution to journalArticle

Related by journal

  1. TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi

    Hector, J., Anderson, S. T., Banda, G., Kamdolozi, M., Jefferys, L. F., Shani, D., Garton, N. J., Mwale, A., Jobe, A., Davies, G. R. & Sloan, D. J. 11 Apr 2017 In : BMC Infectious Diseases. 17, 7 p., 259

    Research output: Contribution to journalArticle

  2. Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum

    Drevinek, P., Holden, M. T. G., Ge, Z., Jones, A. M., Ketchell, I., Gill, R. T. & Mahenthiralingam, E. 19 Sep 2008 In : BMC Infectious Diseases. 8, 16 p., 121

    Research output: Contribution to journalArticle

ID: 254689688